Hims & Hers reported third-quarter revenue of roughly $890 million on Monday, a 49 percent increase from the same period last year. The number landed while the telehealth company fights a federal lawsuit, absorbs a board investigation and fields roughly 4,800 consumer complaints collected over five years.

The company paired the earnings with a governance move: Stanford neuroscientist and podcaster Andrew Huberman will join its board of directors. The appointment signals a bet that credibility in the wellness market can offset mounting questions about consumer trust.

For practitioners watching the model, the quarter shows a business still compounding despite regulatory friction. The question is whether growth outpaces the cost of defending it.

What did the numbers show?

The subscriber base grew 13 percent year-over-year to nearly 2.8 million. Average monthly revenue per subscriber rose 30 percent to $105 — a bigger engine of growth than new sign-ups, which tells you the company is extracting more from each customer rather than simply acquiring more of them.

Geography split sharply:

• Domestic revenue increased 21 percent.
• International revenue increased more than 300 percent, making it the fastest-moving line in the report.

Profitability moved the other way. The company posted a net loss of $33 million for the quarter and lowered its full-year adjusted EBITDA guidance to between $257 million and $277 million. Management is trading margin for expansion, and international growth is the stated direction of that spend.

Why is the FTC suing the company?

In July, the U.S. Federal Trade Commission sued Hims & Hers with three core allegations:

• The company shared users' health data with Meta and Snap Inc.
• It charged customers for prescriptions before they met with a clinician.
• It made subscriptions difficult to cancel.

The FTC said it had received roughly 4,800 complaints about the company over the past five years. That complaint volume matters for operators because it converts a single enforcement action into a pattern the agency can cite across the telehealth sector.

What does the board probe change?

In August, plaintiffs' law firm Berger Montague announced an investigation into whether the company's board had breached its fiduciary duties. The probe runs parallel to the FTC case and targets directors rather than the business itself — a distinction that raises the personal stakes for anyone sitting on the board.

That context frames the Huberman appointment. A new director stepping in while a fiduciary-duty investigation is open accepts exposure along with the seat.

Hims & Hers told Inc. at the time that it would "vigorously defend" itself against the claims. The company has not conceded ground on any allegation.

What should practitioners take from this?

The quarter proves demand and legal risk can grow together. A 30 percent jump in revenue per subscriber to $105 a month shows pricing power that most consumer health brands cannot match — comparable to what a premium subscription media business earns, not a pharmacy.

But the guidance cut to $257 million-$277 million in adjusted EBITDA, combined with a $33 million net loss, shows the cost side catching up. Legal defense, international expansion and subscriber monetization are now competing for the same dollars.

The next checkpoint is the FTC case. How the data-sharing allegations with Meta and Snap resolve will set a benchmark for every telehealth platform that runs ad-targeting on health information. Until then, Hims & Hers keeps growing into the risk rather than away from it.